Europe Intraoperative Radiation Therapy Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Intraoperative Radiation Therapy Market Size

• The Europe intraoperative radiation therapy market size was valued at USD 113.54 million in 2025 and is expected to reach USD 199.50 million by 2033, at a CAGR of 7.3% during the forecast period
•  The market growth is largely fueled by increasing adoption of IORT systems across oncology centers, rising cancer incidence rates, supportive healthcare investments, and technological advancements in targeted radiation delivery platforms that reduce exposure to healthy tissues
• Furthermore, growing demand for precision oncology solutions that can be integrated into surgical workflows for single‑session radiation delivery in breast‑conserving and other cancer surgeries, plus favorable reimbursement initiatives across several European countries, are establishing intraoperative radiation therapy as an essential modality within cancer care pathways. These converging factors are accelerating the uptake of IORT solutions, thereby significantly boosting the industry’s growth across Europe

Europe Intraoperative Radiation Therapy Market Analysis

• Intraoperative radiation therapy market, offering targeted radiation delivery directly to cancerous tissues during surgery, is increasingly critical in modern oncology care due to its precision, reduced treatment times, and minimized exposure to surrounding healthy tissues
• The escalating demand for intraoperative radiation therapy is primarily driven by rising cancer incidence rates, increasing adoption of precision oncology solutions, growing investments in advanced cancer treatment infrastructure, and a preference for single-session, surgery-integrated radiation therapies
• Germany dominated the Europe intraoperative radiation therapy market with the largest revenue share of 29.4% in 2025, characterized by advanced healthcare infrastructure, early adoption of innovative cancer therapies, and strong presence of key industry players, with hospitals and oncology centers experiencing substantial growth in IORT installations
• Poland is expected to be the fastest-growing country in the Europe intraoperative radiation therapy market during the forecast period due to improving healthcare infrastructure, increasing awareness of advanced cancer treatments, and rising government support for oncology initiatives
• Breast cancer application segment dominated the Europe intraoperative radiation therapy market with a market share of 48% in 2025, driven by its established efficacy in breast-conserving surgeries and strong clinical adoption supported by favorable treatment outcomes

Report Scope and Europe Intraoperative Radiation Therapy Market Segmentation  

Europe Intraoperative Radiation Therapy Market Trends

Integration with Advanced Imaging and Precision Oncology

• A significant and accelerating trend in the Europe intraoperative radiation therapy market is the increasing integration of IORT systems with advanced imaging technologies and precision oncology workflows. This combination enhances treatment accuracy and minimizes radiation exposure to surrounding healthy tissues
  • For instance, the INTRABEAM system integrates with real-time imaging platforms, allowing surgeons to visualize the tumor bed during breast-conserving surgery and deliver precise radiation doses. Similarly, Mobetron units can be adapted with intraoperative CT and MRI guidance for other tumor types
• Integration with precision oncology enables treatment personalization based on tumor characteristics and surgical margins, allowing improved patient outcomes and optimized radiation dosage. For instance, certain Xoft Axxent systems adjust radiation delivery parameters based on intraoperative tissue density and tumor cavity mapping.
• The seamless incorporation of IORT into surgical and oncology workflows facilitates coordinated care across multidisciplinary teams, improving overall treatment efficiency and reducing the need for multiple hospital visits
• This trend toward more precise, patient-specific, and workflow-integrated radiation therapy is reshaping clinical expectations in oncology. Consequently, companies such as Carl Zeiss Meditec are developing IORT systems compatible with both surgical navigation tools and hospital information systems
• The adoption of IORT with advanced imaging and integration into precision oncology is growing rapidly across European cancer centers, as hospitals increasingly prioritize reduced treatment times and enhanced patient safety
• Collaborations between device manufacturers and hospital IT departments to integrate IORT data into electronic health records (EHRs) are becoming common, enabling better tracking of treatment outcomes and long-term patient follow-up

Europe Intraoperative Radiation Therapy Market Dynamics

Driver

Increasing Cancer Burden and Adoption of Single-Session Treatments

• The rising incidence of cancers across Europe, coupled with the preference for single-session, surgery-integrated radiation therapies, is a significant driver for Europe intraoperative radiation therapy market growth
  • For instance, in March 2025, Carl Zeiss Meditec reported an expansion of INTRABEAM installations in German hospitals for breast cancer surgeries, aiming to improve access to intraoperative radiation therapy
• As clinicians focus on precision treatment and minimizing patient exposure, IORT offers targeted radiation during surgery, reducing the need for post-operative radiotherapy sessions and hospital visits
• Furthermore, increasing hospital investments in advanced cancer care infrastructure and supportive reimbursement policies are driving the uptake of IORT systems in Europe
• The convenience of delivering radiation intraoperatively, coupled with improved patient outcomes and reduced overall treatment time, is propelling adoption across oncology centers in both public and private sectors
• Rising collaborations between oncology centers and medical device companies are accelerating clinical trials and approvals, promoting faster deployment of IORT systems across European hospitals
• Growing patient preference for minimally disruptive treatment schedules and reduced hospital visits is further increasing demand for single-session, surgery-integrated IORT procedures

Restraint/Challenge

High Costs and Limited Clinical Awareness

• The relatively high initial cost of IORT systems, including equipment, training, and maintenance, poses a significant challenge to broader market adoption in Europe
  • For instance, budget constraints in smaller hospitals or clinics limit access to advanced systems such as Mobetron or INTRABEAM, delaying adoption despite clinical benefits
• Limited awareness among some clinicians and patients regarding the advantages of IORT over conventional post-operative radiotherapy can hinder uptake in certain countries
• While clinical evidence supports improved outcomes in breast-conserving and select tumor surgeries, reluctance to invest in new technology without extensive local trials can slow adoption
• Overcoming these challenges through cost optimization, training programs for surgeons and staff, and awareness campaigns highlighting clinical efficacy will be vital for sustained growth in the Europe intraoperative radiation therapy market
• Maintenance costs, availability of trained personnel, and service infrastructure for IORT devices can pose additional hurdles for hospitals, especially in smaller or rural facilities
• Regulatory approvals and differing reimbursement policies across European countries can slow market penetration and limit access to IORT systems in certain regions, requiring harmonized guidelines for faster adoption

Europe Intraoperative Radiation Therapy Market Scope

The market is segmented on the basis of method, product, type, application, end user, and distribution channel.

• By Method

On the basis of method, the Europe intraoperative radiation therapy market is segmented into Electron IORT, Intraoperative Brachytherapy, High Dose-Rate (HDR) IORT, X-Ray IORT, and Others. The Electron IORT segment dominated the market in 2025 with the largest revenue share of 35%, driven by its established efficacy in delivering precise radiation doses during surgical procedures. Hospitals and cancer centers often prefer Electron IORT for its ability to treat deep-seated tumors while minimizing exposure to surrounding healthy tissue. The high adoption is further supported by availability of established devices, extensive clinical validation, and integration with surgical workflows in breast, head & neck, and soft tissue cancers. Its versatility across multiple tumor types also reinforces its dominance in the market. Electron IORT remains a preferred choice in Western European countries due to established reimbursement policies and clinician familiarity.

The Intraoperative Brachytherapy segment is expected to witness the fastest growth from 2026 to 2033, fueled by increasing adoption in minimally invasive surgeries and advancements in applicator designs. This method offers highly localized radiation delivery, reducing the need for multiple post-operative sessions. Its growing use in gynecological and breast cancers, along with integration with real-time imaging systems, is driving rapid adoption. Expanding clinical awareness and favorable outcomes in early-stage tumors also support its growth trajectory across Europe.

• By Product

On the basis of product, the market is segmented into intraoperative radiation therapy devices, accessories, and software & services. The Intraoperative Radiation Therapy Devices segment dominated in 2025 with the largest share of 62%, owing to its critical role in delivering precise intraoperative radiation during surgeries. Hospitals invest heavily in devices like INTRABEAM and Mobetron for their proven efficacy, ease of integration into operating rooms, and regulatory approvals. Devices are preferred for their reliability, versatility across cancer types, and compatibility with imaging guidance systems. Continuous innovation by leading players in device design, mobility, and energy optimization further solidifies their market dominance. Clinical preference for device-based treatments and high capital investment in established European oncology centers reinforce this leadership.

The Software & Services segment is anticipated to witness the fastest growth from 2026 to 2033, driven by increasing use of planning, monitoring, and workflow management solutions in IORT procedures. Software integration helps surgeons and oncologists track treatment parameters, optimize radiation doses, and maintain patient records efficiently. Rising adoption of treatment planning systems and AI-enabled analytics in European hospitals supports rapid growth. Growing demand for post-procedure data analysis, predictive treatment outcomes, and hospital IT integration further propels this segment.

• By Type

On the basis of type, the market is segmented into portable and benchtop systems. The Portable segment dominated the market in 2025 with the largest revenue share of 57%, attributed to its flexibility and ability to be deployed in multiple operating rooms without major infrastructural changes. Portable IORT systems facilitate quick installation, ease of movement within hospitals, and reduced surgical downtime. They are widely preferred in mid-sized hospitals and ambulatory surgical centers that require adaptable treatment solutions. Additionally, portability allows European hospitals to optimize utilization across multiple departments, improving return on investment. High clinician familiarity and proven outcomes reinforce the dominance of portable IORT devices.

The Benchtop segment is expected to witness the fastest growth from 2026 to 2033, driven by their increasing adoption in specialized cancer centers offering high-precision procedures. Benchtop systems provide enhanced stability, higher radiation dose capacity, and improved integration with imaging systems. Their use in pediatric, gynecological, and complex tumor surgeries is expanding rapidly. Growing hospital infrastructure investments and clinical validation studies highlighting precision and safety are supporting this growth.

• By Application

On the basis of application, the market is segmented into breast cancer, brain tumor, head & neck cancer, soft tissue sarcoma, pediatric tumors, gynecological cancer, genitourinary cancers, upper gastro-intestinal tumors, and other cancer. The Breast Cancer segment dominated the market with a share of 48% in 2025, driven by the high prevalence of breast cancer in Europe and strong clinical evidence supporting improved outcomes with IORT. Single-session, surgery-integrated treatment is highly preferred by patients and clinicians alike. Widespread hospital adoption, favorable reimbursement policies, and reduced post-operative radiation schedules reinforce dominance. The segment also benefits from extensive device compatibility and standardized protocols across European oncology centers.

The Brain Tumor segment is expected to witness the fastest growth from 2026 to 2033, fueled by technological advancements in precision radiation delivery and imaging guidance. Increasing awareness of minimally invasive treatment options and rising incidence of gliomas and metastatic brain tumors are driving adoption. Specialized neurosurgical centers across Germany, France, and the U.K. are increasingly implementing IORT for intraoperative radiation in delicate brain surgeries. Favorable clinical outcomes and growing research initiatives further support rapid growth.

• By End User

On the basis of end user, the market is segmented into hospital, ambulatory surgical centers, specialty centers, and others. The Hospital segment dominated in 2025 with the largest share of 70%, attributed to its established infrastructure, availability of trained oncology and surgical staff, and capital investment capability. Hospitals offer multi-disciplinary oncology care, making them the preferred setting for IORT procedures across Europe. Adoption is further driven by reimbursement policies, patient volume, and integration with existing cancer care pathways.

The Ambulatory Surgical Centers segment is expected to witness the fastest growth from 2026 to 2033, driven by the increasing trend of minimally invasive surgeries and outpatient procedures. These centers benefit from lower operational costs, high patient convenience, and growing adoption of portable IORT systems. Expansion of day-care oncology services in countries like Poland, Spain, and Italy supports rapid growth. Collaboration with device manufacturers ensures the consistent technical support.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct, tender, and retail sales. The Direct segment dominated in 2025 with a market share of 65%, as hospitals and specialty centers prefer direct procurement from manufacturers to ensure compliance, training, and post-sales support. Direct channels allow for customized solutions, technical guidance, and installation support for IORT devices. Leading manufacturers in Germany, France, and the U.K. emphasize direct sales to strengthen client relationships and ensure high-quality service.

The Tender segment is expected to witness the fastest growth from 2026 to 2033, driven by increasing government and public hospital investments in oncology infrastructure. Tenders facilitate bulk procurement at competitive pricing and encourage adoption in emerging markets within Europe. Governments and public institutions in Eastern European countries are increasingly leveraging tender-based procurement for standardized IORT device deployment. It allow smaller hospitals to gradually invest in advanced IORT technology without heavy upfront costs.

Europe Intraoperative Radiation Therapy Market Regional Analysis

• Germany dominated the Europe intraoperative radiation therapy market with the largest revenue share of 29.4% in 2025, characterized by advanced healthcare infrastructure, early adoption of innovative cancer therapies, and strong presence of key industry players, with hospitals and oncology centers experiencing substantial growth in IORT installations
• Clinicians and hospitals in Germany highly value the precision, reduced treatment times, and seamless integration of IORT systems into surgical workflows, particularly for breast, brain, and soft tissue cancers
• This widespread adoption is further supported by well-established oncology care pathways, favorable reimbursement policies, availability of trained surgical and radiation staff, and growing patient awareness, establishing IORT as a preferred intraoperative cancer treatment solution across German hospitals and specialty centers

The Germany Intraoperative Radiation Therapy Market Insight

The Germany IORT market dominated Europe with the largest revenue share in 2025, fueled by advanced healthcare infrastructure, early adoption of innovative cancer treatment technologies, and a strong presence of leading device manufacturers. German hospitals highly value the precision, workflow integration, and reduced treatment times offered by IORT systems. Growing awareness among patients and clinicians, coupled with favorable reimbursement policies and a focus on minimally invasive, single-session procedures, is further driving adoption. Integration with surgical navigation tools and imaging systems, along with robust clinical support and training programs, is reinforcing Germany’s leadership in the European market.

U.K. Intraoperative Radiation Therapy Market Insight

The U.K. IORT market is expected to grow at a substantial CAGR during the forecast period, driven by increasing demand for enhanced cancer care, adoption of advanced surgical technologies, and hospital investments in precision radiation systems. Rising patient awareness regarding intraoperative treatment benefits, coupled with NHS initiatives promoting outpatient and minimally invasive procedures, is supporting market growth. U.K. hospitals are incorporating IORT into breast-conserving surgeries and complex tumor treatments, further stimulating adoption. Collaborative research programs and clinical trials are enhancing confidence in IORT procedures across the country.

France Intraoperative Radiation Therapy Market Insight

The France IORT market is projected to expand steadily, fueled by well-developed oncology infrastructure, favorable reimbursement policies, and growing clinician preference for intraoperative therapies. French cancer centers increasingly utilize IORT for breast, gynecological, and soft tissue tumors due to its precision and reduced patient hospital visits. Clinical awareness campaigns, training initiatives, and government support for advanced cancer therapies are encouraging wider adoption. Hospitals are also investing in portable and benchtop IORT systems to optimize treatment delivery and operational efficiency.

Italy Intraoperative Radiation Therapy Market Insight

The Italy IORT market is witnessing growth due to increasing hospital investments in advanced cancer care, rising prevalence of breast and soft tissue cancers, and adoption of minimally invasive surgical procedures. Hospitals prioritize IORT for single-session radiation delivery, improving patient convenience and reducing overall treatment costs. Integration with imaging and surgical planning systems enhances treatment accuracy and clinician confidence. Awareness programs, clinical validation studies, and collaborations with leading device manufacturers are further supporting market expansion.

Europe Intraoperative Radiation Therapy Market Share

The Europe Intraoperative Radiation Therapy industry is primarily led by well-established companies, including:

• Elekta AB (Sweden)
• IntraOp Medical, Inc. (U.S.)
• Carl Zeiss Meditec AG (Germany)
• Eckert & Ziegler AG (Germany)
• iCAD, Inc. (U.S.)
• Sensus Healthcare, Inc. (U.S.)
• Ariane Medical Systems Ltd (U.K.)
• GMV Innovating Solutions S.L. (Spain)
• Ion Beam Applications SA (Belgium)
• IsoRay, Inc. (U.S.)
• Brainlab AG (Germany)
• Mevion Medical Systems, Inc. (U.S.)
• Xoft, Inc. (U.S.)
• Panacea Medical Technologies Pvt. Ltd. (India)
• REMEDI Co., Ltd. (South Korea)
• RaySearch Laboratories AB (Sweden)
• Sordina IORT Technologies (Italy)
• Zap Surgical Systems Inc. (U.S.)
• Varian Medical Systems, Inc. (U.S.)

What are the Recent Developments in Europe Intraoperative Radiation Therapy Market?

• In December 2025, ZEISS published a compendium of peer‑reviewed clinical articles on IORT usage across various oncological indications, including brain metastasis surgery outcomes and comparative clinical evaluations. This release indicates ongoing scientific dissemination and clinical validation of IORT approaches in Europe, supporting evidence‑based practice
• In October 2025, industry data highlighted expanded IORT technology adoption and collaborations, including Carl Zeiss AG expanding its IORT portfolio with new miniaturized applicators optimized for brain and GI cancer surgeries, and Elekta AB entering a strategic partnership with GMV to enhance IORT treatment planning software with AI‑based dose optimization. This reflects active innovation and clinical focus in the IORT segment that impacts European oncology centers
• In April 2025, Carl Zeiss Meditec AG received FDA 510(k) clearance for its next‑generation INTRABEAM 700 platform, a robotic‑assisted intraoperative radiotherapy system designed to enhance precision and digital workflow for IORT in neuro‑oncology and breast cancer surgery. The platform incorporates robotic precision, digital connectivity, and advanced applicator positioning features, marking a key technology milestone for intraoperative radiation therapy systems globally
• In June 2024, the ILEXIUM 2024 International Low Energy X‑Ray IORT User Meeting was held in Munich, Germany, bringing together global experts to share first‑hand clinical and technological insights on intraoperative radiotherapy use in cancer care, fostering knowledge exchange and practice adoption across Europe
• In April 2022, clinicians at Cáceres University Hospital in Spain treated additional patients under the GLIOX trial using the Xoft System for intraoperative radiation therapy (IORT), expanding applications beyond early‑stage breast cancer to include recurrent glioblastoma (GBM), brain metastases, and head and neck tumors. The campaign also involved treatment at Miguel Servet University Hospital in Zaragoza for sarcomas, brain metastases, over 700 breast cancers, and more than 200 gynecological cancers

SKU-64142